Analysts See $-0.02 EPS for BioPharmX Corporation (BPMX) on June, 12

May 17, 2018 - By Loretta Love

BioPharmX Corporation (NYSEAMERICAN:BPMX) Corporate Logo

On June, 12 is awaited BioPharmX Corporation (NYSEAMERICAN:BPMX)’s earnings report, as reported by Faxor. Analysts forecast $-0.02 earnings per share. That’s $0.05 up or 71.43 % from 2017’s earnings of $-0.07. BPMX is touching $0.191 during the last trading session, after decreased 1.55%.BioPharmX Corporation has volume of 2.24M shares. Since May 17, 2017 BPMX has declined 50.58% and is downtrending. BPMX underperformed by 62.13% the S&P500.

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter products that address dermatology and women's health markets.The firm is valued at $36.58 million. The firm offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and for the alleviation of symptoms of fibrocystic breast condition (FBC).Currently it has negative earnings. The Company’s clinical-stage product candidates include BPX03, a molecular iodine tablet, which is in pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia; and BPX01, a topical antibiotic gel that is in Phase IIb clinical trial for the treatment of acne vulgaris.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.